COVID-Influenza Combo Vaccine Candidate Presents Positive Data

BioSpace reported today Vivek Shinde, vice president of clinical development and lead for older adult influenza & RSV vaccines at Novavax Inc., delivered an update on the Company's COVID-influenza combination (CIC) candidate at the World Vaccine Congress 2023.

The Company presented CIC data and poster presentations on its COVID-19 prototype vaccine during this conference in Washington, DC.

Shinde confirmed that CIC formulations were immunogenic and induced strong functional antibody and CD4+ T cell responses against SARS-CoV-2 and multiple influenza strains on April 5, 2023.

"I think a combination vaccine is only going to hopefully boost compliance in those who intend to get both vaccines," he informed Heather McKenzie at BioSpace on April 7, 2023.

Novavax intends to use these data to inform an ongoing Phase II dose confirmation study. Results from this study are expected later in 2023.

Novavax's COVID-19 vaccine (Nuvaxovid™, CovoVax™, NVX-CoV2373) protein-based vaccine has received various  authorizations from more than 43 countries.